3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
venetoclax
91
Azacitidine
75
Cytarabine
68
Specimen Handling
45
fludarabine
44
Biopsy
32
Cyclophosphamide
29
Daunorubicin
27
fludarabine phosphate
25
Injections
25
Decitabine
25
Idarubicin
24
Busulfan
20
Granulocyte Colony-Stimulating Factor
19
Whole-Body Irradiation
18
Mycophenolic Acid
18
Tacrolimus
17
Melphalan
17
decitabine and cedazuridine drug combination
16
gilteritinib
14
Stem Cell Transplantation
14
CPX-351
14
Mitoxantrone
13
Peripheral Blood Stem Cell Transplantation
11
Magnetic Resonance Spectroscopy
11
Filgrastim
11
Etoposide
11
Cladribine
11
ivosidenib
10
revumenib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Acute
×
Inosine Monophosphate
×
90 days
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled